Chinese Expert Consensus on the Treatment of Cardioembolic Stroke (2022 edition)

Title: Chinese Expert Consensus on the Treatment of Cardioembolic Stroke (2022 edition)
Edition: Original
Classification: Experts consensus
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users: This consensus will be helpful for neurologists and related departments or professionals.
Evidence classification method: Classification method-GRADE
Development unit: Group of Geriatric Neurology, Chinese Society of Geriatrics, Chinese Medical Association;Vascular Neurology Committee, Beijing Neuroscience Society;Chinese Expert consensus group on the treatment of cardiogenic stroke
Registration time: 2022-10-15
Registration number: PREPARE-2022CN650
Purpose of the guideline: Cardioembolic stroke (CES) is a clinical syndrome in which emboli from the heart and aortic arch pass through the circulation and cause cerebral artery embolism, resulting in corresponding cerebral dysfunction. Compared with ischemic stroke caused by other causes, CES has more complex etiology, more severe condition, worse prognosis and higher recurrence rate. Most CES patients have definite heart diseases or risk factors, of which about 70% are caused by atrial fibrillation (AF). Although there has been progress in the prevention and treatment of CES (such as AF at high risk of stroke) in recent years, there are still some problems such as insufficient understanding and large differences in treatment strategies. In view of the above problems, and there is no comprehensive and unified treatment plan for CES (especially for the acute phase) at home and abroad, the consensus development group formulated this expert consensus based on the clinical research at home and abroad in recent years, combined with the actual situation in China, in order to better standardize the treatment of CES and improve the clinical treatment level of CES.